The notices it replaced
- Reissues: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 2 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-13-235.
Who won it before
36 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,302,320 in first-year total cost, median $223,901.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OTC-T (10)]5
- Special Emphasis Panel[ZRG1 IMST-M (13)]3
- Special Emphasis Panel[ZRG1 VH-F (10)]3
- Special Emphasis Panel[ZRG1 ETTN-M (11)]2
- Special Emphasis Panel[ZRG1 MOSS-S (10)]2
Most frequent institutions
- ADEPTHERA, LLC1
- APEX BIOMEDICAL COMPANY, LLC1
- BLACKROCK MICROSYSTEMS1
- CELL BIOLOGICS, INC.1
- CHEMOFILTER, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Computer-based Prescription Opioid Abuse Prevention for Adolescents2R42DA023731-02 · under PA-10-051 | MARSCH, LISA A. | HEALTHSIM, INC., NY | $450,459 | ZRG1 |
| 2014 | Infant Assessment of Early Communication Risk Factors : The ISCBS (formerly ECBS)2R42DC012009-02 | CRESS, CYNTHIA J | PAUL H. BROOKES PUBLISHING COMPANY, INC., MD | $389,759 | ZRG1 |
| 2014 | Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury2R42NS074734-02 | BOTTLANG, MICHAEL | APEX BIOMEDICAL COMPANY, LLC, OR | $385,311 | ZRG1 |
| 2014 | Novel commensal polysaccharide treats multiple sclerosis through Treg modulation1R41AI110170-01 | KASPER, LLOYD H | SYMBIOTIX BIOTHERAPIES, INC., MA | $322,928 | ZRG1 |
| 2014 | Multi-Blot Western Device1R41GM106494-01A1 | CHIEN, STANLEY YUNG-PING | YC BIOELECTRIC, LLC, IN | $307,787 | ZRG1 |
| 2014 | Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay1R41AI104377-01A1 · under PA-12-089 | BAUMAN, SEAN | IMMUNO-MYCOLOGICS, INC., OK | $299,640 | ZRG1 |
| 2014 | Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury1R42NS086274-01 | KEANE, ROBERT W | INFLAMACORE, LLC, FL | $240,656 | ZRG1 |
| 2014 | Novel Small Molecule Therapeutics for Pancreatic Cancer1R41CA176931-01A1 | CASHMAN, JOHN RCHEN, SIGENGOKOLOTOWICZ, KARL J | CHEMREGEN INC, CA | $240,555 | ZRG1 |
| 2014 | An innovative in situ cell reprogramming technology for cancer treatment1R41CA183103-01 | JIANG, FENGLI, QIANQIANWANG, JIANJUN | QURGEN, INC., MI | $225,000 | ZRG1 |
| 2014 | Development of VPL Vaccine for RSV1R41AI109926-01 | BLANCO, JORGE C | SIGMOVIR BIOSYSTEMS, INC., MD | $225,000 | ZRG1 |
| 2014 | Orally available transition state inhibitors for triple negative breast cancer1R41CA183201-01 | ISAACMAN, STEVENSCHRAMM, VERN L. | NANOMETICS, LLC, CA | $225,000 | ZRG1 |
| 2014 | DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis1R41CA192567-01 | WALISH, JOSEPH | DYNUPOL, INC., MA | $225,000 | ZRG1 |
| 2014 | Assessing muscle health in older adults with electrical impedance myography1R41AG047021-01 | BEAN, JONATHAN FBOHORQUEZ, JOSE LUIS | MYOLEX, INC., MA | $225,000 | ZRG1 |
| 2014 | Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp1R41CA183266-01 | HAZLEHURST, LORI AMCLAUGHLIN, MARK L | MODULATION THERAPEUTICS, INC., WV | $225,000 | ZRG1 |
| 2014 | Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema1R41CA183335-01 | HSU, SHEAU-YU TEDDY | ADEPTHERA, LLC, CA | $225,000 | ZRG1 |
| 2014 | ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment1R41CA183327-01 | PATEL, ANAND S | CHEMOFILTER, INC., CA | $224,999 | ZRG1 |
| 2014 | A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease1R41AA024029-01 · under PA-12-089 | BADER, ANDREAS GYU, AIMING | MIRNA THERAPEUTICS, INC., TX | $224,996 | ZRG1 |
| 2014 | Novel scFv-Antibody Fusion siRNA Carrier Protein for Macroglobulinemia Treatment1R41CA186101-01 | GARAVITO, R MICHAEL | SIRNAX, INC., MI | $224,921 | ZRG1 |
| 2014 | Targeting the chondrosarcoma extracellular matrix for drug delivery1R41CA183208-01 | HOHL, RAYMOND J. | TERPENOID THERAPEUTICS, INC., IA | $222,881 | ZRG1 |
| 2014 | Selective activation of the vagus nerve as an improved therapy for heart failure1R41HL121897-01 | DOWDEN, BRETT ROSS | BLACKROCK MICROSYSTEMS, UT | $222,049 | ZRG1 |
| 2014 | Cblb-based Drugs Against Sepsis and Inflammation1R41HL118896-01A1 | BACHMAIER, KURTGAO, XIAO-PEI | CELL BIOLOGICS, INC., IL | $218,510 | ZRG1 |
| 2014 | Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells1R41CA176962-01A1 | CHERVIN, ADAM | IMMUVEN, INC., IL | $218,309 | ZRG1 |
| 2014 | Transdermal H2S Sensing Device for Monitoring Peripheral Artery Disease1R41HL121871-01 | KANAGY, NANCY LSHEKARRIZ, REZA | EXHALIX, LLC, NM | $215,724 | ZRG1 |
| 2014 | High Z Oraya Therapy for wet AMD1R41EY024197-01 | CHELL, ERIK WILLIAMMAKRIGIORGOS, G. MIKE | ORAYA THERAPEUTICS, INC, CA | $215,200 | ZRG1 |
| 2014 | Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma1R41CA183197-01 | MILLS, KEVIN D | CYTEIR THERAPEUTICS, INC., MA | $213,466 | ZRG1 |
| 2014 | Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI1R41MD008809-01 | LILLARD, JAMES W | HAPLOMICS, INC., CA | $203,849 | ZRG1 |
| 2014 | Multi-functional particles for stem cell isolation and expansion1R41MH106303-01 | HU, WENJING | PROGENITEC, INC., TX | $200,251 | ZRG1 |
| 2014 | Picture Me Fit: Engaging Youth in Community-Based Prevention1R41NR015736-01A1 · under PA-12-089 | STRACK, ROBERT W. | PREVENTION STRATEGIES, LLC, NC | $197,524 | ZRG1 |
| 2014 | New Functionally-Graded Biohybrid Vascular Graft1R41TR001009-01A1 · under PA-12-089 | VOHRA, YOGESH K. | VIVO BIOSCIENCES, INC., AL | $192,314 | ZRG1 |
| 2014 | Mitochondrial Uncoupling as a Therapeutic Target in Obesity1R41DK097862-01A1 | SULLIVAN, PATRICK G | NANO-MITE TECHNOLOGIES, LLC, KY | $183,070 | ZRG1 |
| 2014 | Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel1R41CA183315-01 | MONTGOMERY, JEFFREY SCOTT | PRODEVICE MEDICAL SUPPLIES AND EQUIPMENT, MI | $161,003 | ZRG1 |
| 2014 | Manufacture of Self-Reporting, Drug Loaded Porous Silicon Nanomaterials for Treat1R41EY023482-01 · under PA-12-089 | ANGLIN, EMILY JESSICA | SPINNAKER BIOSCIENCES, INC., CA | $159,384 | ZRG1 |
| 2014 | Minimal piggyBac vectors for chromatin integration1R41GM109527-01 | SOLODUSHKO, VICTOR | EXSCIEN CORPORATION, AL | $150,576 | ZRG1 |
| 2014 | Surface-covering gels for broad-spectrum antimicrobial protection following open1R41AR065917-01 | VERNON, BRENT L | SONORAN BIOSCIENCES, INC., AZ | $149,967 | ZRG1 |
| 2014 | A daily client check-in system for outpatient substance abuse treatment1R41DA036949-01 | CARSWELL, STEVEN BERNARD | COG ANALYTICS, LLC, MD | $147,735 | ZRG1 |
| 2014 | Science Take-Out Kits for Environmental Health Education1R41ES023706-01 | HOLT, SUSANMARKOWITZ, DINA GROSSMAN | SCIENCE TAKE-OUT, LLC, NY | $143,497 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.